The forecast for anxiolytic medicine sales in Canada from 2024 to 2028 shows a gradual decline. In 2023, the value was not mentioned, but starting in 2024 with 137.1 million CAD, there is a consistent downward trend, with a year-on-year decrease as follows: 1.60% from 2024 to 2025, 1.63% from 2025 to 2026, 1.66% from 2026 to 2027, and 1.61% from 2027 to 2028. The five-year CAGR indicates a steady average decline as well. These variations denote a declining market, possibly due to changing medical practices or regulatory influences.
Future trends to watch for include:
- New anxiolytic drug developments or advancements that could invigorate sales.
- Changes in healthcare policies or mental health awareness increasing demand.
- Potential shifts in consumer preferences towards alternative treatments.
